Philippe Giron

Dr. Philippe Giron

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ANAmir Noeparast
Amir Noeparast
ETErik Teugels
Erik Teugels
PGPhilippe Giron
Philippe Giron
GVGil Verschelden
Gil Verschelden
SBSylvia De Brakeleer
Sylvia De Brakeleer
JGJacques De Grève
Jacques De Grève
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

8 July 2019 in Oncogene
Verified
Journal Article
Open access
PDF file
ANAmir Noeparast
Amir Noeparast
PGPhilippe Giron
Philippe Giron
ANAlfiah Noor
Alfiah Noor
RSRajendra Bahadur Shahi
Rajendra Bahadur Shahi
SBSylvia De Brakeleer
Sylvia De Brakeleer
ETErik Teugels
Erik Teugels
Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAFP261A and CRAFP207S. To our knowledge, both mutations are novel in lung cancer and CRAFP261A has not been previously reported in cancer. Expression of CRAFP261A in HEK293T cells and BEAS-2B lung epithelial cells led to increased ERK pathway activation in a dimer-dependent manner, accompanied with loss of CRAF phosphorylation at the negative regulatory S259 residue. Moreover, stable expression of CRAFP261A in mouse embryonic fibroblasts and BEAS-2B cells led to anchorage-independent growth. Consistent with a previous report, we could not observe a gain-of-function with CRAFP207S. Type II but not type I RAF inhibitors suppressed the CRAFP261A-induced ERK pathway activity in BEAS-2B cells, and combinatorial treatment with type II RAF inhibitors and a MEK inhibitor led to a stronger ERK pathway inhibition and growth arrest. Our findings suggest that the acquisition of a CRAFP261A mutation can provide oncogenic properties to cells, and that such cells are sensitive to combined MEK and type II RAF inhibitors. CRAF mutations should be diagnostically and therapeutically explored in lung and perhaps other cancers.

8 August 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
MEMara Esposito
Mara Esposito
HAH. Begum Akman
H. Begum Akman
PGPhilippe Giron
Philippe Giron
MCM. Angeles Ceregido
M. Angeles Ceregido
RSRogier Schepers
Rogier Schepers
GGGustavo J. Gutierrez
Gustavo J. Gutierrez

27 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
ANAmir Noeparast
Amir Noeparast
PGPhilippe Giron
Philippe Giron
SBSylvia De Brakeleer
Sylvia De Brakeleer
CECarolien Eggermont
Carolien Eggermont
URUlrike De Ridder
Ulrike De Ridder
JGJacques De Grève
Jacques De Grève
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

22 December 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZRZhuo Ren
Zhuo Ren
JAJoeri L Aerts
Joeri L Aerts
HVHugo Vandenplas
Hugo Vandenplas
JWJiance A Wang
Jiance A Wang
OGOlena Gorbenko
Olena Gorbenko
JGJacques De Grève
Jacques De Grève
Signal transducer and activator of transcription 5 (STAT5) and nucleophosmin (NPM1) are critical regulators of multiple biological and pathological processes. Although a reciprocal regulatory relationship was established between STAT5A and a NPM–ALK fusion protein in T-cell lymphoma, no direct connection between STAT5 and wild-type NPM1 has been documented. Here we demonstrate a mutually regulatory relationship between STAT5 and NPM1. Induction of STAT5 phosphorylation at Y694 (P-STAT5) diminished NPM1 expression, whereas inhibition of STAT5 phosphorylation enhanced NPM1 expression. Conversely, NPM1 not only negatively regulated STAT5 phosphorylation but also preserved unphosphorylated STAT5 level. Mechanistically, we show that NPM1 downregulation by P-STAT5 is mediated by impairing the BRCA1-BARD1 ubiquitin ligase, which controls the stability of NPM1. In turn, decreased NPM1 levels led to suppression of p53 expression, resulting in enhanced cell survival. This study reveals a new STAT5 signaling pathway regulating p53 expression via NPM1 and uncovers new therapeutic targets for anticancer treatment in tumors driven by STAT5 signaling.

22 June 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Cabirou Mounchili ShintouoCabirou Mounchili Shintouo
Cabirou Mounchili Shintouo
RSRobert Adamu SHEY
Robert Adamu SHEY
DNDerrick Neba Nebangwa
Derrick Neba Nebangwa
KEKevin Esoh
Kevin Esoh
NNNkemngo Francis Nongley
Nkemngo Francis Nongley
Rose NjeminiRose Njemini
Rose Njemini
The public health goal of onchocerciasis in Africa has advanced from control to elimination. In this light, accurate diagnosis is necessary to determine treatment endpoints and confirm elimination, as well as to conduct surveillance for the identification of any possible recrudescence of the disease. Currently, the monitoring of onchocerciasis elimination relies on the Ov-16 test. However, this test is unable to discriminate between past and active infections. Furthermore, about 15–25% of infected persons are reported to be negative for the Ov-16 test, giving a misleading sense of security to false-negative individuals who might continue to serve as reservoirs for infections. Therefore, we opted to design and validate a more sensitive and specific chimeric antigen (OvMANE1) for onchocerciasis diagnosis, using previously reported immunodominant peptides of O. volvulus, the parasite responsible for the disease. In silico analysis of OvMANE1 predicted it to be more antigenic than its individual peptides. We observed that OvMANE1 reacts specifically and differentially with sera from O. volvulus infected and non-infected individuals, as well as with sera from communities of different levels of endemicity. Moreover, we found that total IgG, unlike IgG4 subclass, positively responded to OvMANE1, strongly suggesting its complementarity to the Ov-16 diagnostic tool, which detects Ov-16 IgG4 antibodies. Overall, OvMANE1 exhibited the potential to be utilized in the development of specific diagnostic tools—based on both antibody capture and antigen capture reactions—which are indispensable to monitor the progress of onchocerciasis elimination programs.